Form 4: Rezolute CCO Granted 32,000 RSUs and 19,000 Options

Rezolute, Inc.'s Chief Commercial Officer, Sunil Ratilal Karnawat, was granted 32,000 restricted stock units and 19,000 employee stock options, effective November 19, 2025.

Summary

• Sunil Ratilal Karnawat, Chief Commercial Officer of Rezolute, Inc., reported changes in beneficial ownership.
• Karnawat was granted 32,000 common shares in the form of restricted stock units (RSUs) on November 19, 2025, with a price of $0.
• These RSUs will vest annually over a three-year period, with the first vesting on December 1, 2026.
• Karnawat also acquired 19,000 employee stock options on November 19, 2025, with an exercise price of $10.16.
• These options have an expiration date of November 19, 2035, and vest 1/36th monthly starting December 19, 2025.
• Following these transactions, Karnawat directly owns 59,442 common shares and 19,000 employee stock options.
• Indirect holdings include 8,000 common shares in an Individual Retirement Account and 1,898 common shares in a Health Savings Account.

Sentiment

Score: 7

Explanation: The filing reports standard executive compensation grants, which are generally positive for aligning management incentives with shareholder interests, but do not indicate any immediate operational or financial performance changes.

Positives

• The grant of restricted stock units and employee stock options aligns the Chief Commercial Officer's interests with long-term shareholder value.
• The vesting schedules for both RSUs (three years) and options (36 months) incentivize long-term commitment and performance from a key executive.

Negatives

• No explicit negatives are present in this Form 4 filing, which primarily reports compensation grants.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The vesting schedules for the granted RSUs and options indicate a long-term incentive structure for the Chief Commercial Officer, aligning future performance with equity value over the next three years and beyond.

Industry Context

This filing reflects standard executive compensation practices within the biotechnology or pharmaceutical industry, where equity grants are common tools to attract, retain, and incentivize key personnel by linking their compensation to company performance and shareholder value.

Comparison to Industry Standards

• The grant of RSUs and stock options to a Chief Commercial Officer is a common practice in the biotech and pharmaceutical sectors, comparable to compensation structures at companies like Amgen, Gilead Sciences, or Biogen, which frequently use equity-based incentives to align executive interests with long-term company growth.
• The vesting periods (three years for RSUs, 36 months for options) are typical for executive equity grants, designed to encourage sustained performance and retention, similar to programs observed at peer companies.
• The exercise price of $10.16 for the options would be compared to the market price of RZLT shares on the grant date to assess if they were granted at-the-money, which is standard for incentive stock options.

Related Party Transactions

• Grant of 32,000 restricted stock units to Chief Commercial Officer Sunil Ratilal Karnawat.
• Grant of 19,000 employee stock options to Chief Commercial Officer Sunil Ratilal Karnawat.

Stakeholder Impact

• Shareholders: The grants align the Chief Commercial Officer's interests with long-term shareholder value, potentially leading to more focused efforts on company growth and stock performance.
• Employees: May signal stability in executive leadership and a commitment to retaining key talent.

Next Steps

• The restricted stock units will begin vesting on December 1, 2026.
• The employee stock options will begin vesting monthly starting December 19, 2025.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation in the form of equity grants. While these grants align management incentives with shareholder interests, they do not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive corporate updates.

Keywords

Rezolute, RZLT, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Executive Compensation, Sunil Karnawat, Beneficial Ownership